Dr. George Discusses Treatment of Uterine Leiomyosarcoma

Suzanne George, MD
Published: Tuesday, Dec 18, 2018



Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the evolving treatment paradigm for patients with uterine leiomyosarcoma.

Uterine sarcomas are extremely rare, George says, accounting for approximately 3% of uterine cancers. Due to their low incidence rates, it is difficult to detect uterine sarcomas in their early stages. Recent studies suggest that chemotherapy regimens with docetaxel, gemcitabine, or anthracycline have activity in these patients. Each of these drugs has similar efficacy, and George says that is important for patients to understand that they have multiple treatment options available to them.

With the advent of olaratumab (Lartruvo), a novel PDGF antibody, and its approval in the United States and Europe, the paradigm has expanded even further. The addition of olaratumab to doxorubicin resulted in an overall survival advantage when compared with doxorubicin alone in patients with metastatic soft tissue sarcoma, including those with leiomyosarcoma.

A confirmatory phase III trial is currently underway, according to George, who added that olaratumab is also being evaluated in combination with other chemotherapies to better understand how this agent might further be used in the general treatment of patients with soft tissue sarcomas and in the subset of patients with uterine sarcomas.
SELECTED
LANGUAGE


Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the evolving treatment paradigm for patients with uterine leiomyosarcoma.

Uterine sarcomas are extremely rare, George says, accounting for approximately 3% of uterine cancers. Due to their low incidence rates, it is difficult to detect uterine sarcomas in their early stages. Recent studies suggest that chemotherapy regimens with docetaxel, gemcitabine, or anthracycline have activity in these patients. Each of these drugs has similar efficacy, and George says that is important for patients to understand that they have multiple treatment options available to them.

With the advent of olaratumab (Lartruvo), a novel PDGF antibody, and its approval in the United States and Europe, the paradigm has expanded even further. The addition of olaratumab to doxorubicin resulted in an overall survival advantage when compared with doxorubicin alone in patients with metastatic soft tissue sarcoma, including those with leiomyosarcoma.

A confirmatory phase III trial is currently underway, according to George, who added that olaratumab is also being evaluated in combination with other chemotherapies to better understand how this agent might further be used in the general treatment of patients with soft tissue sarcomas and in the subset of patients with uterine sarcomas.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian CancerJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x